Celularity
About Celularity
Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses.YEAR FOUNDED:
August 2017
LEADERSHIP:
Founder & CEO: Robert J. Hariri, MD, PhD.
114 articles about Celularity
-
Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on “The Science and Technology for Extending Healthy Human Lifespan”
11/30/2022
Celularity, Inc., a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared that Chairperson, Founder and Chief Executive Officer Robert J. Hariri, M.D., Ph.D. addressed the Future Investment Initiative 6th Edition in Riyadh conference sponsored by the Future Investment Initiative at the plenary session: The Science and Technology for Extending Healthy Human Lifespan.
-
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
11/10/2022
Imugene Limited (ASX:IMU) are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the renowned Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/10/2022
Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September 30, 2022, and provided a corporate update.
-
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
11/10/2022
Celularity Inc. today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab.
-
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
Celularity Promotes Two Executives in Executive Leadership Team
10/6/2022
Celularity Inc., a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies, announced the promotion of two senior executives and the formation of a new Executive Committee.
-
Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical OfficerVeteran pharmaceutical executive brings more than 15 years of proven oncology and immunology experience
10/3/2022
Celularity Inc. today announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today.
-
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
9/27/2022
Celularity Inc. today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET.
-
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro
9/26/2022
Celularity Inc. today announced publication of a study in Frontiers in Immunology describing the antiviral role of its placental-derived natural killer (NK) cells (CYNK) in IAV infections.
-
Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville
9/15/2022
Celularity Inc., a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, announced that it entered into a Pre-Paid Advance Agreement with YA II PN, LTD, an affiliate of Yorkville Advisors Global, LP.
-
Celularity Announces Participation in Upcoming September 2022 Investor Conferences
9/6/2022
Celularity Inc. announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will participate in fireside chats at the following investor conferences:
-
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
8/9/2022
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
7/27/2022
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that the first patient has been treated with CYNK-101.
-
Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform
7/19/2022
Antengene Corporation Limited today announced that it has entered into a pre-clinical research collaboration with Celularity Inc.
-
Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®
6/8/2022
Celularity Inc. announced it is set to join the broad-market Russell 3000 and the Russell 2000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted June 3, 2022.
-
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
6/3/2022
Celularity Inc., a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, announced the appointment of Diane Parks to its Board of Directors.
-
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/16/2022
Celularity Inc. announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.
-
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
-
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/31/2022
Celularity Inc. (Nasdaq: CELU) (“Celularity”), today reported a corporate update and financial results for the fourth quarter and full year ended December 31, 2021.